Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ATWLPPR Peptide TFA is a selective neuropilin-1 inhibitor and inhibits VEGF165 binding to NRP-1. It has the potential in reducing the early retinal damage caused by diabetes.
产品描述 | ATWLPPR Peptide TFA is a selective neuropilin-1 inhibitor and inhibits VEGF165 binding to NRP-1. It has the potential in reducing the early retinal damage caused by diabetes. |
体外活性 | ATWLPPR Peptide TFA inhibits VEGF165 binding to NRP-1 by 82% at 100 μM [1]. |
体内活性 | ATWLPPR (400 μg/kg, s.c.) preserves vascular integrity and decreases the oxidative stress level, possibly reduces the early retinal damage caused by diabetes. ATWLPPR prevents the increase of inflammation-associated proteins (GFAP, VEGF, and ICAM-1) in the retina [2]. |
分子量 | 954 |
分子式 | C42H62F3N11O11 |
CAS No. | T10408 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 50 mg/mL (52.41 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O | 1 mM | 1.0482 mL | 5.2411 mL | 10.4822 mL | 26.2055 mL |
5 mM | 0.2096 mL | 1.0482 mL | 2.0964 mL | 5.2411 mL | |
10 mM | 0.1048 mL | 0.5241 mL | 1.0482 mL | 2.6205 mL | |
20 mM | 0.0524 mL | 0.2621 mL | 0.5241 mL | 1.3103 mL | |
50 mM | 0.021 mL | 0.1048 mL | 0.2096 mL | 0.5241 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ATWLPPR Peptide TFA T10408 Others Inhibitor inhibitor inhibit